Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRTX0902 in advanced solid tumors with KRAS MAPK mutations
NCT05578092Phase 1Terminated
- Sponsor
- Mirati Therapeutics
- Start
- Dec 2022
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of MRTX0902 in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 21 days and Treatment-Related Adverse Event at 2 years. Started Dec 2022; status: terminated.
02
Drugs
MRTX0902
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05578092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578092.